Millennium Management LLC Has $7.99 Million Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Millennium Management LLC increased its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 91.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 424,137 shares of the company's stock after purchasing an additional 202,419 shares during the quarter. Millennium Management LLC owned approximately 0.56% of Nurix Therapeutics worth $7,991,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. FMR LLC raised its stake in Nurix Therapeutics by 1,711.9% in the fourth quarter. FMR LLC now owns 10,634,231 shares of the company's stock valued at $200,349,000 after buying an additional 10,047,329 shares during the last quarter. Vanguard Group Inc. raised its stake in Nurix Therapeutics by 8.3% in the fourth quarter. Vanguard Group Inc. now owns 4,345,266 shares of the company's stock valued at $81,865,000 after buying an additional 333,452 shares during the last quarter. Wellington Management Group LLP raised its stake in Nurix Therapeutics by 3.0% in the fourth quarter. Wellington Management Group LLP now owns 3,586,605 shares of the company's stock valued at $67,572,000 after buying an additional 104,500 shares during the last quarter. Geode Capital Management LLC raised its stake in Nurix Therapeutics by 9.5% in the fourth quarter. Geode Capital Management LLC now owns 1,585,127 shares of the company's stock valued at $29,870,000 after buying an additional 137,087 shares during the last quarter. Finally, RA Capital Management L.P. acquired a new position in shares of Nurix Therapeutics in the fourth quarter valued at about $25,120,000.

Nurix Therapeutics Trading Up 5.3%

NRIX traded up $0.53 on Thursday, hitting $10.57. 515,101 shares of the company were exchanged, compared to its average volume of 871,812. Nurix Therapeutics, Inc. has a twelve month low of $8.18 and a twelve month high of $29.56. The company has a market cap of $805.81 million, a price-to-earnings ratio of -3.67 and a beta of 2.23. The firm has a 50-day moving average price of $10.45 and a two-hundred day moving average price of $16.03.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its earnings results on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.05. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. The firm had revenue of $18.45 million during the quarter, compared to analysts' expectations of $12.78 million. During the same period in the previous year, the firm posted ($0.76) EPS. Equities analysts expect that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently commented on the company. Wells Fargo & Company dropped their target price on Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating on the stock in a report on Wednesday, April 9th. Royal Bank of Canada raised their price objective on Nurix Therapeutics from $26.00 to $27.00 and gave the company an "outperform" rating in a report on Wednesday, January 29th. Needham & Company LLC restated a "buy" rating and issued a $27.00 target price on shares of Nurix Therapeutics in a research report on Tuesday, April 29th. Stifel Nicolaus decreased their target price on Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating on the stock in a research report on Wednesday, April 9th. Finally, JPMorgan Chase & Co. reduced their price objective on Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 29th. One analyst has rated the stock with a sell rating, three have issued a hold rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $30.44.

Insiders Place Their Bets

In other Nurix Therapeutics news, CFO Houte Hans Van sold 6,198 shares of the business's stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $11.33, for a total transaction of $70,223.34. Following the transaction, the chief financial officer now owns 33,724 shares in the company, valued at approximately $382,092.92. The trade was a 15.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Gwenn Hansen sold 3,377 shares of the company's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total value of $38,835.50. Following the completion of the sale, the insider now owns 61,516 shares in the company, valued at approximately $707,434. This represents a 5.20% decrease in their position. The disclosure for this sale can be found here. Insiders sold 17,838 shares of company stock valued at $221,500 in the last ninety days. Insiders own 7.40% of the company's stock.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.